Contents

List of Contributors XV
Preface XIX
Personal Foreword XXI

Part One Natural Products as Sources of Potential Drugs and Systematic Compound Collections 1

1 Natural Products as Drugs and Leads to Drugs: An Introduction and Perspective as of the End of 2012 3
David J. Newman and Gordon M. Cragg
1.1 Introduction 3
1.2 The Sponge-Derived Nucleoside Link to Drugs 5
1.3 Initial Recognition of Microbial Secondary Metabolites as Antibacterial Drugs 8
1.4 β-Lactams of All Classes 9
1.5 Tetracycline Derivatives 12
1.6 Glycopeptide Antibacterials 13
1.7 Lipopeptide Antibacterials 16
1.8 Macrolide Antibiotics 18
1.9 Pleuromutilin Derivatives 19
1.10 Privileged Structures 21
1.11 The Origin of the Benzodiazepines 21
1.12 Benzopyrans: A Source of Unusual Antibacterial and Other Agents 22
1.13 Multiple Enzymatic Inhibitors from Relatively Simple Natural Product Secondary Metabolites 23
1.14 A Variation on BIOS: The “Inside–Out” Approach 26
1.15 Other Privileged Structures 26
1.16 Privileged Structures as Inhibitors of Protein–Protein Interactions 27
1.17 Underprivileged Scaffolds 30
## 3.3 Synthesis and Biological Activity of Non-natural Epothilones

### 3.3.1 Semisynthetic Derivatives

### 3.3.2 Fully Synthetic Analogs

- **3.3.2.1** Polyketide-Based Macrocycles
- **3.3.2.2** Aza-Epothilones (Azathilones)
- **3.3.2.3** Hybrid Structures and Acyclic Analogs

### 3.4 Conformational Studies and Pharmacophore Modeling

### 3.5 Conclusions

## 4 Taxol, Taxoids, and Related Taxanes

*Iwao Ojima, Anushree Kamath, and Joshua D. Seitz*

### 4.1 Introduction and Historical Background

- **4.1.1** Discovery of Taxol (Paclitaxel): An Epoch-Making Anticancer Drug from Nature

### 4.1.2 Taxane Family

### 4.1.3 Sources and Methods of Production

- **4.1.3.1** Extraction from Yew Trees
- **4.1.3.2** Semisynthesis
- **4.1.3.3** Total Synthesis
- **4.1.3.4** Biotechnology Processes

### 4.1.4 Clinical Development of Taxol (Taxol®)

### 4.2 Mechanism of Action and Drug Resistance

- **4.2.1** Taxol, Cell Cycle Arrest, and Apoptosis
- **4.2.2** Drug Resistance to Taxol

### 4.3 Structure-Activity Relationships (SAR) of Taxol

- **4.3.1** SAR of Taxol
- **4.3.2** Chemical Modifications of Taxol: Taxol Derivatives and Taxoids

#### 4.3.2.1 Modifications in the C13 Side Chain

#### 4.3.2.2 Modification in the Baccatin Component

#### 4.3.2.3 Prodrugs of Taxol

### 4.4 Structural and Chemical Biology of Taxol

#### 4.4.1 Bioactive Conformation of Taxol

#### 4.4.2 Microtubule-Binding Kinetics of Taxol

### 4.5 New-Generation Taxoids from 10-DAB

#### 4.5.1 Taxoids from 10-DAB

#### 4.5.2 Taxoids from 14β-Hydroxybaccatin III

#### 4.5.3 Taxoids from 9-Dihydrobaccatin III

### 4.6 Taxoids in Clinical Development

- **4.6.1** Docetaxel (Taxotere®, RP 56976)
- **4.6.2** Cabazitaxel (Jevtana®, RPR 116258A, XRP6258)
- **4.6.3** Larotaxel (XRP9881, RPR109881)
- **4.6.4** Ortataxel (SB-T-101131, IDN5109, BAY59-8862, ISN 5109)
5  Camptothecin and Analogs  181
   Giuseppe Giannini
5.1  Introduction  181
5.2  Biology Activity  185
5.2.1  Camptothecin Acts on Eukaryotic Top 1  187
5.2.2  Drug Resistance and Topoisomerase Mutation  189
5.2.3  Camptothecin: Beyond the Topoisomerase I  190
5.2.4  Off-Label Investigation  190
5.3  Camptothecin in Clinical Use and Under Clinical Trials  190
5.3.1  Homocamptothecin  203
5.4  Chemistry  204
5.4.1  Total Syntheses  205
5.4.2  Syntheses of Some Representative Camptothecin Derivatives  207
5.5  Structure–Activity Relationship  210
5.6  Xenograft Studies  211
5.7  Prodrug/Targeting  212
5.8  Developments of Modern Chromatographic Methods Applied to
   CPT  214
5.9  Conclusions and Perspectives  214
References  215

6  A Short History of the Discovery and Development of Naltrexone and
   Other Morphine Derivatives  225
   Vimal Varghese and Tomas Hudlicky
6.1  Introduction  225
6.2  History and Development  226
6.3  Pharmacology  238
6.4  Structure–Activity Relationship of Morphine and its Analogs  240
6.5  Conclusions and Outlook  244
References  244

7  Lincosamide Antibacterials  251
   Hardwin O’Dowd, Alice L. Enwin, and Jason G. Lewis
7.1  Introduction  251
7.2  Mechanism of Action  253
7.3  Antibacterial Spectrum  254
8  Platensimycin and Platencin  271
   Arun K. Ghosh and Kai Xi
   8.1  Introduction and Historical Background  271
   8.2  Discovery and Bioactivities of Platensimycin and Platencin  272
   8.3  Total and Formal Syntheses of Platensimycin  278
   8.4  Total and Formal Syntheses of Platencin  283
   8.5  Analogs of Platensimycin and Platencin  287
   8.6  Conclusions and Perspective  295
   References  296

9  From Natural Product to New Diabetes Therapy: Phlorizin and the Discovery of SGLT2 Inhibitor Clinical Candidates  301
   Vincent Mascitti and Ralph P. Robinson
   9.1  Introduction  301
   9.2  Phlorizin: A Drug Lead from Apple Trees  302
   9.3  Phlorizin: Mechanism of Action  304
   9.4  Phlorizin, SGLTs, and Diabetes  306
   9.5  Phlorizin Analogs: O-Glucosides  306
   9.6  Phlorizin Analogs: C-Glucosides  309
   9.7  C-Glucosides: Aglycone Modifications  314
   9.8  C-Glucosides: Sugar Modifications  316
   9.9  Conclusions  325
   References  325

10 Aeruginosins as Thrombin Inhibitors  333
    Juan R. Del Valle, Eric Therrien, and Stephen Hanessian
    10.1  Introduction  333
    10.2  Targeting the Blood Coagulation Cascade  333
    10.3  Structure of Thrombin  335
    10.4  The Aeruginosin Family  336
    10.4.1  Aeruginosin 298A and Related Microcystis sp. Peptides  336
    10.4.2  Oscillarin and Related Oscillatoria sp. Peptides  339
    10.4.3  Dysinosin A and Related Peptides from Dysidaedae Sponges  340
    10.4.4  Structurally Related Antithrombin Peptide Natural Products  342
    10.4.5  Close Analogs of Antithrombotic Aeruginosins  344
    10.5  Mimicking Nature  346
    10.5.1  The 50-Year Challenge  348
    10.5.2  Peptide Analogs  350
    10.5.3  Peptidomimetics  352
Part Three  Natural Products as an Incentive for Enabling Technologies  365

11  Macrolides and Antifungals via Biotransformation  367
    Aaron E. May and Chaitan Khosla

11.1 Introduction to Polyketides and Their Activity  367
11.2 Mechanism of Polyketide Biosynthesis  367
  11.2.1 Erythromycin  371
  11.2.2 Avermectin/Doramectin  377
  11.2.3 Tetracyclines  381
  11.2.4 Salinosporamides  385
11.3 Conclusions  391
    References  392

12  Unnatural Nucleoside Analogs for Antisense Therapy  403
    Punit P. Seth and Eric E. Swayze

12.1 Nature Uses Nucleic Acid Polymers for Storage, Transfer, Synthesis, and Regulation of Genetic Information  403
12.2 The Antisense Approach to Drug Discovery  404
12.3 The Medicinal Chemistry Approach to Oligonucleotide Drugs  406
12.4 Structural Features of DNA and RNA Duplexes  407
12.5 Improving Binding Affinity of Oligonucleotides by Structural Mimicry of RNA  410
  12.5.1 2'-Modified RNA  411
    12.5.1.1 2'-O-Me RNA  411
    12.5.1.2 2'-O-Methoxyethyl RNA  412
    12.5.1.3 2'-Fluoro RNA  413
  12.5.2 2',4'-Bridged Nucleic Acids  414
    12.5.2.1 2',4'-Constrained MOE and 2',4'-Constrained Ethyl BNA  415
    12.5.2.2 5'-Me-LNA  416
    12.5.2.3 Carbocyclic LNA Analogs  417
    12.5.2.4 Ring-Expanded BNA Analogs  417
    12.5.2.5 α,β-Bridged Nucleic Acids  418
    12.5.3 Hexitol Nucleic Acids  420
  12.6 Improving Binding Affinity of Oligonucleotides by Conformational Restraint of DNA – the Bicyclo- and Tricyclo-DNA Class of Nucleic Acid Analogs  421
  12.7 Improving Binding Affinity of Oligonucleotides by Conformational Restraint of the Phosphodiester Backbone – α,β-Constrained Nucleic Acids  423
12.8 Naturally Occurring Backbone Modifications  424
12.8.1 The Phosphorothioate Modification 425
12.9 Naturally Occurring Heterocycle Modifications 426
12.9.1 5-Substituted Pyrimidine Analogs 427
12.10 Outlook 428
References 429

13 Hybrid Natural Products 441
Keisuke Suzuki and Yoshizumi Yasui

13.1 Introduction 441
13.2 Staurosporines (Amino Acid–Sugar Hybrids) 444
13.2.1 Occurrence 444
13.2.2 Bioactivity 445
13.2.3 Biosynthesis 446
13.2.4 Synthesis 446
13.2.5 Medicinal Chemistry 447
13.3 Lincomycins (Amino Acid–Sugar Hybrids) 448
13.3.1 Occurrence 448
13.3.2 Bioactivity 448
13.3.3 Biosynthesis 448
13.3.4 Medicinal Chemistry 449
13.4 Madindolines (Amino Acid–Polyketide Hybrids) 449
13.4.1 Occurrence 449
13.4.2 Bioactivity 450
13.4.3 Synthesis 451
13.5 Kainoids (Amino Acid–Terpene Hybrids) 451
13.5.1 Occurrence 451
13.5.2 Bioactivity 451
13.5.3 Biosynthesis 453
13.5.4 Synthesis 453
13.5.5 Medicinal Chemistry 453
13.6 Benanomicin–Pradimicin Antibiotics (Sugar–Polyketide Hybrids) 455
13.6.1 Occurrence 455
13.6.2 Bioactivity 455
13.6.3 Medicinal Chemistry 456
13.6.4 Synthesis 457
13.7 Angucyclines (Sugar–Polyketide Hybrids) 457
13.7.1 Occurrence and Biosynthesis 457
13.7.2 Bioactivity 459
13.7.3 Synthesis 460
13.8 Furaquinocins (Polyketide–Terpene Hybrids) 462
13.8.1 Occurrence 462
13.8.2 Biosynthesis 464
13.8.3 Synthesis 464
13.9 Conclusions 467
References 467
14 Rethinking the Role of Natural Products: Function-Oriented Synthesis, Bryostatin, and Bryologs 475
Paul A. Wender, Alison C. Donnelly, Brian A. Loy, Katherine E. Near, and Daryl Staveness

14.1 Introduction 475
14.2 Introduction to Function-Oriented Synthesis 476
14.2.1 Representative Examples of Function-Oriented Synthesis 478
14.3 Introduction to Bryostatin 489
14.4 Bryostatin Total Syntheses 493
14.4.1 Total Syntheses of Bryostatins 2, 3, and 7 (1990–2000) 493
14.4.2 Total Synthesis of Bryostatin 16 (2008) 494
14.4.3 Total Synthesis of Bryostatin 1 (2011) 495
14.4.4 Total Synthesis of Bryostatin 9 (2011) 495
14.4.5 Total Synthesis of Bryostatin 7 (2011) 495
14.5 Application of FOS to the Bryostatin Scaffold 496
14.5.1 Initial Pharmacophoric Investigations on the Bryostatin Scaffold 498
14.5.2 Design of the First Synthetically Accessible Functional Bryostatin Analogs 500
14.5.3 Initial Preclinical Investigations of Functional Bryostatin Analogs 508
14.5.4 Des-A-Ring Analogs 510
14.5.5 C13-Functionalized Analogs 514
14.5.6 B-Ring Dioxolane Analog 516
14.5.7 C20 Analogs 518
14.5.8 C7 Analogs 520
14.5.9 A-Ring Functionalized Bryostatin Analogs 522
14.5.10 New Methodology: Prins-Driven Macrocyclization Toward B-Ring Pyran Analogs 527
14.5.11 A-Ring Functionalized Analogs and Induction of Latent HIV Expression 529
14.6 Conclusions 533

References 533

15 Cyclopamine and Congeners 545
Philipp Heretsch and Athanassios Giannis

15.1 Introduction 545
15.2 The Discovery of Cyclopamine 545
15.3 Accessibility of Cyclopamine 547
15.4 The Hedgehog Signaling Pathway 549
15.5 Medical Relevance of Cyclopamine and the Hedgehog Signaling Pathway 551
15.5.1 Models of Cancer Involving the Hedgehog Signaling Pathway 551
15.5.2 Hedgehog Signaling Pathway Inhibitors for the Treatment of Pancreatic Cancer, Myelofibrosis, and Chondrosarcoma 552
Part Five  Nature: The Provider, the Enticer, and the Healer  565

16  Hybrids, Congeners, Mimics, and Constrained Variants Spanning 30 Years of Natural Products Chemistry: A Personal Retrospective  567
    Stephen Hanessian
16.1  Introduction  567
16.2  Structure-Based Organic Synthesis  570
16.3  Nucleosides  572
16.3.1  Quantamycin  572
16.3.2  Malayamycin A  573
16.3.3  Hydantocidin  573
16.4  β-Lactams  576
16.4.1  Analog Design  576
16.4.2  Unnatural β-Lactams  577
16.5  Morphinomimetics  579
16.6  Histone Deacetylase Inhibitors  580
16.6.1  Acyclic Inhibitors  581
16.6.2  Macro cyclic Inhibitors  582
16.7  Pactamycin Analogs  583
16.8  Aeruginosins: From Natural Products to Achiral Analogs  586
16.8.1  Structure-Based Hybrids and Truncated Analogs  586
16.8.2  Constrained Peptidomimetics  589
16.8.3  Achiral Inhibitors  589
16.9  Avermectin B₁₉ and Bafilomycin A₁  591
16.10  Bafilomycin A₁  592
16.11  3-N,N-Dimethylamino Lincomycin  594
16.12  Oxazolidinone Ketolide Mimetics  595
16.13  Epilogue  596
    References  598

Index  611